MX2023013557A - Pauta posologica de sotorasib. - Google Patents

Pauta posologica de sotorasib.

Info

Publication number
MX2023013557A
MX2023013557A MX2023013557A MX2023013557A MX2023013557A MX 2023013557 A MX2023013557 A MX 2023013557A MX 2023013557 A MX2023013557 A MX 2023013557A MX 2023013557 A MX2023013557 A MX 2023013557A MX 2023013557 A MX2023013557 A MX 2023013557A
Authority
MX
Mexico
Prior art keywords
sotorasib
dosing regimen
cancer
patient
kras
Prior art date
Application number
MX2023013557A
Other languages
English (en)
Inventor
Sandeep Dutta
Joseph Park
Gregory Friberg
Haby Henary
Gataree Ngarmchamnanrith
Brett E Houk
Omar Mather
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023013557A publication Critical patent/MX2023013557A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos para tratar un cáncer que comprende una mutación en KRAS G12C en un paciente con metástasis cerebrales activas, que comprende administrar sotorasib al paciente en la cantidad efectiva para tratar el cáncer.
MX2023013557A 2021-05-18 2022-05-17 Pauta posologica de sotorasib. MX2023013557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163190061P 2021-05-18 2021-05-18
PCT/US2022/029677 WO2022245857A1 (en) 2021-05-18 2022-05-17 Sotorasib dosing regimen

Publications (1)

Publication Number Publication Date
MX2023013557A true MX2023013557A (es) 2023-11-29

Family

ID=82019614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013557A MX2023013557A (es) 2021-05-18 2022-05-17 Pauta posologica de sotorasib.

Country Status (7)

Country Link
EP (1) EP4340842A1 (es)
JP (1) JP2024519060A (es)
CN (1) CN117355306A (es)
AU (1) AU2022277860A1 (es)
CA (1) CA3218575A1 (es)
MX (1) MX2023013557A (es)
WO (1) WO2022245857A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024072437A1 (en) * 2022-09-30 2024-04-04 Amgen Inc. Sotorasib dosing regimen

Also Published As

Publication number Publication date
CA3218575A1 (en) 2022-11-24
CN117355306A (zh) 2024-01-05
WO2022245857A1 (en) 2022-11-24
EP4340842A1 (en) 2024-03-27
JP2024519060A (ja) 2024-05-08
AU2022277860A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
PH12020551908A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
MX2020009773A (es) Terapia de combinacion.
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
WO2018102687A3 (en) Combination therapy for treating cancer
MX2020001727A (es) Terapia de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
MX2019013862A (es) Terapia de combinacion.
MX2023013557A (es) Pauta posologica de sotorasib.
MX2020009842A (es) Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
MX2021008972A (es) Terapia de combinacion de quelante metalico para el tratamiento del cancer.
MX2017015532A (es) Terapia de combinacion pac-1.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.